MEI Pharma, Inc.

287 articles with MEI Pharma, Inc.

• MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

  6/9/2021

  MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma to be held June 18 – 22, 2021.

• MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

  6/7/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

• MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting

  6/4/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced it will host an investor and analyst video webcast event on Thursday, June 10, 2021 at 12:00 PM ET following the 2021 American Society of Clinical Oncology Annual Meeting.

• MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021

  5/19/2021

  Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL) who had progression of disease within 24 months of first line chemoimmunotherapy (POD24); overall response rate of 93% in non-POD24

• MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

  5/12/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced updated clinical data from a Phase 1b study of zandelisib,

• MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights

  5/6/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress.

• MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer

  4/30/2021

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Robert Mass, M.D., MEI's chief medical officer.

• MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. FDA

  4/13/2021

  MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced completion of enrollment in the follicular lymphoma primary efficacy population of the global Phase 2 TIDAL study.

• MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers

  4/10/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors.

• MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference

  4/5/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 20th Annual Needham Virtual Healthcare Conference.

• MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models

  3/10/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, was selected for an E-Poster Session presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021

• MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences Conference 2021

  3/2/2021

   MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the virtual H.C. Wainwright Global Life Sciences 2021. The company will present a company overview and business update available for on-demand listening starting Tuesday March 9, 2021

• MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights

  2/4/2021

  --Multiple Clinical Development Milestones Anticipated in 2021-- --MEI Maintains Strong Financial Position with $180 Million in Cash--

• MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

  1/4/2021

  - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies - - MEI provides clinical pipeline outlook for 2021 - - MEI Pharma to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference -

• MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights

  11/10/2020

  --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment-- --MEI Starts Second Fiscal Quarter 2021 with $176.1 Million in Cash--

• MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences - Nov 09, 2020

  11/9/2020

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced its participation in the following upcoming virtual investor conferences:

• MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing

  9/15/2020

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David Urso, chief operating officer and general counsel, effective immediately.

• MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights

  9/9/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2020. 

• MEI Pharma to Present at Upcoming Investor Conferences in September

  9/4/2020

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 at 2:40 p.m. ET H.C. Wainwright

• MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020

  9/2/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2020 fiscal year end financial results after the close of the U.S. financial markets on September 9, 2020. The Company will host a conference call and live webcast wi